Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2019 | Allogeneic CAR-T technology

Bijal Shah • 6 Dec 2019
ASH 2019
Acute Lymphoblastic Leukemia Leukemia CAR-T

Bijal Shah, MD, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, discusses allogeneic or ‘off-the-shelf’ CAR-T technologies and their pros/cons, including their persistence. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

More from Bijal Shah

1:33
The impact of prior therapies on the outcomes of patients with R/R ALL treated with CAR-T therapy
Bijal Shah • 8 Sep 2023
1:27
TP53-aberrant MCL: challenges and treatment approaches
Bijal Shah • 8 Sep 2023
1:03
ECOG-E1910 study: clinical benefit of early blinatumomab incorporation in ALL
Bijal Shah • 8 Sep 2023
1:03
An insight into the sequencing of immunotherapies in adults with ALL
Bijal Shah • 8 Sep 2023

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals